Andere Sprachen Amneal Pharmaceuticals, Inc.

Aktien

A2JLMD

US03168L1052

AMRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 18.04.2024			% 5 Tage	% 1. Jan.
5.36 ^USD	-1.83%		-5.80%	-11.70%

18.04.	Amneal Pharmaceuticals kündigt Einführung von Pemetrexed Injektion, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA) an	CI
12.04.	Bausch Health erhält "positives" Gerichtsurteil zu Xifaxan, obwohl der Markt Bausch + Lomb eine Chance von 32% einräumt, so RBC	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	18.04.
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll	18.04.
Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine	17.04.
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine	16.04.
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	12.04.
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	12.04.
Amneal to Report First Quarter 2024 Results on May 3, 2024	10.04.
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	08.04.
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	08.04.
North American Morning Briefing : Inflation Data, -2-	08.04.
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024	28.03.
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful	28.03.
Amneal Pharmaceuticals : LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful.	27.03.
Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination	25.03.
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment	25.03.
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	25.03.
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	25.03.
Amneal Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	04.03.
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01.03.
Sector Update: Health Care	01.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Amneal Pharmaceuticals, Inc.

Aktien

A2JLMD

US03168L1052

AMRX

Andere Sprachen

Filter